Clinical research studyIncidence and Risk Factors of Venous Thromboembolic Events in Lymphoma
Section snippets
Study Population
This study is a retrospective review of 422 consecutive patients newly referred to the lymphoma department in the MD Anderson Cancer Center from January 2003 to December 2003. All patients received at least 1 cycle of chemotherapy in our hospital. The medical records of these patients were reviewed for all venous thromboembolism events during a follow-up period of 2 years from the referral date. Approval for this retrospective medical record review study was obtained from the Institutional
Patients Characteristics
The study population included 422 eligible lymphoma patients who received at least 1 cycle of chemotherapy (total 2126 cycles) at our hospital in a period of 2 years follow-up from the referral date. The median age of the patients was 57 years (range, 17-87 years), with 58% males and 42% females (Table 1). Most patients (62%) were newly diagnosed, and had advanced stages of the disease (stage III 23.9%, stage IV 50.2%). Eighty-four percent (355/422) of the patients were non-Hodgkin's lymphoma,
Discussion
The purpose of our study was to define the incidence, the timing, and the risk factors predictive of venous thromboembolism in newly referred lymphoma patients at a comprehensive cancer center. Our study demonstrates that the incidence of venous thromboembolism is high in patients with lymphoma, with an overall incidence of 17.1%. Because this study did not prospectively screen for incidental venous thromboembolism, the actual risk may be underestimated in this population. The incidence was
References (32)
- et al.
Incidence of venous thromboembolism in patients hospitalized with cancer
Am J Med
(2006) - et al.
Cancer and venous thromboembolism
Lancet Oncol
(2005) - et al.
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
J Thromb Haemost
(2007) - et al.
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest
(2004) - et al.
The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia
Hematol Oncol Clin North Am
(2008) - et al.
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism
J Thromb Haemost
(2006) - et al.
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study
J Thromb Haemost
(2006) - et al.
In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis
Kidney Int
(2005) - et al.
The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer
Clin Oncol (R Coll Radiol)
(1999) - et al.
Predictive indicators of deep venous thrombosis and pulmonary arterial thromboembolism in 54 subjects after total knee arthroplasty using multislice computed tomography in logistic regression models
Int J Cardiol
(2007)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Blood
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
Lancet
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
Blood
Venous thrombosis in cancer patients: insights from the frontline survey
Oncologist
The long-term clinical course of acute deep venous thrombosis
Ann Intern Med
Incidence of venous thromboembolism and its effect on survival among patients with common cancers
Arch Intern Med
Cited by (52)
Venous thromboembolism and risk stratification in hematological malignancies
2022, Thrombosis ResearchVenous thromboembolism incidence in hematologic malignancies
2019, Blood ReviewsVenous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment
2018, Blood ReviewsCitation Excerpt :It follows that more aggressive thromboprophylaxis in high-risk patients could reduce the mortality rate of lymphoma patients resulting from VTE. In lymphoma patients, the risk of VTE is associated with a variety of factors, which can be categorized as patient-related, lymphoma-related, and treatment-related (Table 1) [4,10–13,15–21,26–30,32–78]. Special consideration must be given to the presence of lupus anticoagulant (LA) in lymphoma patients.
Therapeutic implication of MicroRNA-320a antagonist in attenuating blood clots formed during venous thrombosis
2024, Journal of Thrombosis and Thrombolysis
Funding: Clinical research funding.
Conflict of Interest: The authors indicated no potential conflicts of interest.
Authorship: Saroj Vadhan-Raj, the principal investigator, was responsible for conception and design, execution of the study, analysis and interpretation of the data, and drafting of the article. Xiao Zhou, Shyam Teegala, and Auris Huen assisted with the writing of the protocol and manuscript, coordinated the collection and the statistical analysis of the data and critical review of the article. Yuan Ji was responsible for the statistical analysis and the interpretation of the results. Luis Fayad and Fredrick B. Hagemeister provided the study participants and critically reviewed the article, and Gregory Gladish provided radiologic expertise and critically reviewed the article.